XTENDI
Xtendi is developing an online studio for creating Augmented Reality experiences to design digital layers on physical objects using a simple ‘drag & drop’ interface. Xtendi's studio offers a unique (patent pending) proximity feature that adds a new level of exploration. Users can interact with objects in their surroundings based on their natural human behavior. Just as in the real world when something interests you, you get closer to it to learn more about it, or sometimes you take a step back to see the wider context, Xtendi is mimicking this natural human behavior through AR technology. Xtendi believes that the potential of the technology resides in the USER, that’s why its focus is on the USER INTERACTION aspect of technology.
XTENDI
Industry:
Augmented Reality SaaS Software
Founded:
2012-03-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.xtendi.com
Total Employee:
1+
Status:
Active
Contact:
972544545254
Email Addresses:
[email protected]
Technology used in webpage:
Amazon Amazon Virginia Region Amazon S3 CDN Amazon Elastic Load Balancing Amazon ELB North Virginia
Similar Organizations
BirdOne LLC
Drone Augmented Reality SaaS Company
Cirqus
Events & Entertainment SaaS platform
MondoDX
Industrial Augmented Reality, SaaS
Quark Experiences Pvt. Ltd.
virtual Reality, 360, SaaS platform for VR
Scapic
Virtual/Augmented Reality Start Up .
Current Employees Featured
Founder
Official Site Inspections
http://www.xtendi.com
- Host name: ec2-44-194-137-173.compute-1.amazonaws.com
- IP address: 44.194.137.173
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Xtendi"
XTANDI Support Solutions® Welcome | XTANDI® (enzalutamide)
Jan 10, 2017 For help with XTANDI, please call 1-855-898-2634. For help with PADCEV, please call 1-888-402-0627. For help with CRESEMBA, please call 1-800-477-6472. XTANDI Access …See details»
Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate ...
Enzalutamide (Xtandi) mCSPC – Patient Advocacy Group COI Declarations COI Declarations September 23, 2020 View PDF. Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial …See details»
Pfizer and Astellas' XTANDI - News | Astellas Pharma Inc.
Nov 16, 2023 XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy * in nonmetastatic castration-sensitive prostate …See details»
Prostate Cancer Support Organizations | XTANDI® (enzalutamide) …
Important Safety Information. Warnings and Precautions. Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In a study of patients with predisposing …See details»
Astellas Pharma US, Inc. | News Room - News Releases
XTANDI is an oral, once-daily, androgen receptor signaling inhibitor. It inhibits multiple steps in the androgen receptor signaling pathway, which has been shown to decrease cancer cell …See details»
Xtendi - Crunchbase Company Profile & Funding
Xtendi is developing an online studio for creating Augmented Reality experiences to design digital layers on physical objects using a simple ‘drag & drop’ interface.See details»
Xtandi - European Medicines Agency (EMA)
Feb 25, 2025 Xtandi can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in treating prostate cancer. Xtandi is available …See details»
Contact us - XTANDI
Severe swallowing problems or choking, including life-threatening problems or death can happen in people during treatment with XTANDI, because of the size of the XTANDI capsules and …See details»
XTANDI® (enzalutamide) Receives Health Canada ... - Astellas …
Jan 30, 2024 XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer …See details»
Patient Stories and Resources | XTANDI® (enzalutamide)
Find resources for XTANDI® patients and caregivers, such as the doctor discussion guide, FAQs, clinical glossary, and more. See Risks, Safety Info, and Benefits. ... Malecare is America’s …See details»
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …
XTANDI® (enzalutamide) Product Monograph Page 5 of 59 4.1 Dosing Considerations Xtandi is for use in patients who are maintaining treatment with a GnRH analogue or who have had …See details»
XTANDI® (enzalutamide) Receives Health Canada Approval as
Jan 30, 2024 The approval is based on results from the Phase 3 EMBARK trial of XTANDI (enzalutamide) plus ADT (n=355), placebo plus ADT (n=358), and XTANDI as monotherapy …See details»
XTANDI - News | Astellas Pharma Inc.
Dec 17, 2019 “XTANDI has been established as a standard of care for men with castration-resistant prostate cancer and has been prescribed to more than 420,000 patients worldwide …See details»
enzalutamide - Cancer Care Ontario
Other Name(s): Xtandi® Appearance: white capsule Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the …See details»
Astellas Xtandi Support Solutions
XTANDI Support Solutions offers access and reimbursement support to help patients overcome challenges accessing XTANDI ® (enzalutamide). I AM A HEALTHCARE PROFESSIONAL I …See details»
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term …
3 days ago XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive …See details»
XTANDI® (enzalutamide) Patient Support Solutions® | HCP Site
Important Safety Information. Warnings and Precautions. Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In a study of patients with predisposing …See details»
Astellas Patient Assistance Program | XTANDI® (enzalutamide) …
Jan 10, 2017 For help with XTANDI, please call 1-855-898-2634. For help with PADCEV, please call 1-888-402-0627. For help with CRESEMBA, please call 1-800-477-6472. XTANDI Access …See details»
Astellas And Pfizer's XTANDI Shows Long-Term Survival Benefits In ...
3 days ago XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive …See details»
Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in ...
4 days ago First-Quarter 2023 Revenues of $18.3 Billion . Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues ; First-Quarter …See details»